Farallon Capital Management LLC lessened its holdings in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 94.1% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 27,600 shares of the company’s stock after selling 442,400 shares during the quarter. Farallon Capital Management LLC’s holdings in Altimmune were worth $184,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in the business. Price T Rowe Associates Inc. MD grew its stake in shares of Altimmune by 13.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock valued at $156,000 after acquiring an additional 1,821 shares in the last quarter. North Star Investment Management Corp. acquired a new stake in shares of Altimmune during the first quarter valued at about $31,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Altimmune during the first quarter valued at about $44,000. TFO Wealth Partners LLC acquired a new stake in shares of Altimmune during the first quarter valued at about $51,000. Finally, Arizona State Retirement System grew its stake in shares of Altimmune by 34.4% during the second quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock valued at $132,000 after acquiring an additional 5,081 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.
Insider Transactions at Altimmune
In related news, Director David Drutz sold 16,011 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the completion of the sale, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by insiders.
Altimmune Trading Down 7.6 %
Altimmune (NASDAQ:ALT – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative net margin of 24,778.97% and a negative return on equity of 53.09%. The company had revenue of $0.01 million during the quarter. During the same period in the previous year, the business posted ($0.32) earnings per share. As a group, analysts forecast that Altimmune, Inc. will post -0.54 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on ALT. Evercore ISI upgraded Altimmune to a “strong-buy” rating in a research note on Friday, August 9th. B. Riley restated a “buy” rating and issued a $20.00 target price on shares of Altimmune in a research note on Monday, August 12th. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, August 22nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price target on shares of Altimmune in a report on Friday, June 21st. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.80.
About Altimmune
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
Recommended Stories
- Five stocks we like better than Altimmune
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Average 401k Balance by Age Explained
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Want to see what other hedge funds are holding ALT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Altimmune, Inc. (NASDAQ:ALT – Free Report).
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.